Sotrovimab-linked SARS-CoV-2 mutations emerge in Sydney

Cases of resistance to the biologic demand increased genomic surveillance, virologists say

Signs of SARS-CoV-2 resistance to sotrovimab, the main monoclonal antibody treatment used in Australia, has been detected in a world-first clinical study in Sydney.

Dr Rebecca Rockett
Dr Rebecca Rockett.

The discovery will likely lead to intense genomic monitoring of patients to ensure resistance doesn’t render the drug ineffective, researchers say.

A team examining the first 100 patients to receive